Please assess the completion status of the following clinical trial:

Trial Title: A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with locally advanced or metastatic nonsquamous non-small cell lung cancer~* Patients must be non-smokers~* Patients must have at least one measurable lesion~* Performance status of 0 to 2 on the Eastern Cooperative Oncology Group Scale~* Patients must have failed only one prior chemotherapy regimen and must be considered eligible for further chemotherapy following progression of their disease.~Exclusion Criteria:~* Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication~* Patients who have previously received treatment with drugs against the human epidermal growth factor receptors~* Patients who have previously received treatment with drugs which have similar targets as Pemetrexed~* Patients who have any known significant ophthalmologic abnormalities of the surface of the eye~* Patients who have a history of severe hypersensitivity reaction to erlotinib or pemetrexed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pemetrexed + Erlotinib (Type: EXPERIMENTAL): Pemetrexed 500 milligrams per meter squared (mg/m\^2) of body surface area, administered by intravenous (IV) infusion on Day 1 plus erlotinib 150 mg orally once daily on Day 2 through Day 14 of each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
- Erlotinib (Type: ACTIVE_COMPARATOR): Erlotinib 150 mg, administered orally once daily in each 21-day cycle until disease progression or unacceptable toxicity developed or up to 38 months.
- Pemetrexed (Type: ACTIVE_COMPARATOR): Pemetrexed 500 mg/m\^2 of body surface area, administered by IV infusion on Day 1 of each 21-day cycle until progression or unacceptable toxicity developed or up to 38 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).